Cell Therapy News

Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.

Cellular Trojan Horse Initiates Bimetallic Fe-Cu MOF-Mediated Synergistic Cuproptosis and Ferroptosis Against Malignancies

[Science Advances] Investigators engineered a Cellular Trojan Horse, named MetaCell, which used live neutrophils to stably internalize thermosensitive liposomal bimetallic Fe-Cu MOFs. MetaCell could instigate cuproptosis and ferroptosis, thereby enhancing treatment efficacy.

Characterization of a Novel T Cell-Engaging Bispecific Antibody for Elimination of L1CAM-Positive Tumors

[Biomedicine & Pharmacotherapy] Scientists designed and characterized a novel bispecific antibody based on the IgG-(L)-ScFv format, which targeted L1CAM and CD3 simultaneously.

Efficient CAR T Cell Targeting of the CA125 Extracellular Repeat Domain of MUC16

[Journal For Immunotherapy Of Cancer] Researchers tested a series of antibodies raised against the CA125 extracellular repeat domain of MUC16 and adapted them to the CAR format. Comparisons between these candidates, and against an existing CAR targeting the MUC16 ectodomain, identified K101 as having high potency and specificity.

PD-1 Downregulation Enhances CAR-T Cell Antitumor Efficiency by Preserving a Cell Memory Phenotype and Reducing Exhaustion

[Journal For Immunotherapy Of Cancer] The authors incorporated a short hairpin RNA cassette targeting PD-1 into a B cell maturation antigen-CAR with an OX-40 costimulatory domain.

Identification and Removal of Unexpected Proliferative Off-Target Cells Emerging after iPSC-Derived Pancreatic Islet Cell Implantation

[Proceedings Of The National Academy Of Sciences Of The United States Of America] Investigators showed that the implantation of seven-stage induced PSC-derived pancreatic islet cells led to the emergence of unexpected off-target cells with proliferative capacity via in vivo maturation.

FOXO1 Enhances CAR T Cell Stemness, Metabolic Fitness, and Efficacy

[Nature] Investigators showed that overexpression of FOXO1 promoted a stem-like phenotype in CAR T cells derived from either healthy human donors or patients, which correlated with improved mitochondrial fitness, persistence and therapeutic efficacy in vivo.

Expression and Processing of Mature Human Frataxin after Gene Therapy in Mice

[Scientific Reports] Researchers assessed mature exogenous hFXN expression levels in the heart and liver of C57Bl/6 mice seven-ten months after intravenous administration of a recombinant adeno-associated virus encoding hFXN (AAVrh.10hFXN) and examined the potential for hFXN truncation in mice.

Self-Regulating CAR-T Cells Modulate Cytokine Release Syndrome in Adoptive T Cell Therapy

[Journal Of Experimental Medicine] With a humanized NSG-SGM3 mouse model, investigators showed reduced CRS-related toxicity in mice treated with CAR-T cells secreting tocilizumab-derived single-chain variable fragment, yielding a safety profile superior to that of single-dose systemic tocilizumab administration.

Donor Regulatory T Cells Rapidly Adapt to Recipient Tissues to Control Murine Acute Graft-Versus-Host Disease

[Nature Communications] The authors used a major histocompatibility complex-mismatched mouse model to follow the fate of in vitro expanded donor regulatory T cells upon migration to target organs

CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

[Cancer Discovery] Investigators reported that CTX130 showed favorable preclinical proliferation and cytotoxicity profiles and completely regressed renal cell carcinoma xenograft tumors.

CD4+ CAR-T Cell Exhaustion Associated with Early Relapse of Multiple Myeloma after BCMA CAR-T Cell Therapy

[Blood Advances] While there were no pre-existing T cell features associated with clinical outcomes, scientists found that patients with a durable response to CAR-T cell treatment had greater persistence of their CAR-T cells compared to patients with transient clinical responses.

Phase I Study Combining Elotuzumab with Autologous Stem Cell Transplant and Lenalidomide for Multiple Myeloma

[Journal For Immunotherapy Of Cancer] The authors conducted a Phase I clinical trial to investigate the application of autologous lymphocyte infusion and anti-SLAMF7 monoclonal antibody, elotuzumab, after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma previously treated with induction therapy.

Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.